MYTHOS: trastuzumab deruxtecan in HER2+ salivary gland cancer
Ichiro Kinoshita, MD, PhD, Hokkaido University Hospital, Sapporo, Japan, discusses findings from the Phase II MYTHOS trial (jRCT2011210017), evaluating trastuzumab deruxtecan (T-DXd) in HER2-positive recurrent/metastatic salivary gland cancer. The study showed an encouraging objective response rate and common grade 3/4 adverse events included neutropenia and lymphopenia, with manageable interstitial lung disease. These promising results support T-DXd as a potential therapeutic option for this rare cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
